Catalyst
Slingshot members are tracking this event:
Agenus (AGEN) Doses First Patient in Phase 1/2 Study Evaluating AGEN2034 in Advanced Tumors and Cervical Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AGEN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 20, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1/2, Agen2034, Advanced Tumors, Cervical Cancer
